Tokyo Tape
Sign in
← M3

Half-year report · Q2

2413.TEDINET S100UO9S
Period2024-04-01 → 2024-09-30
Filed2024-11-08
StandardIFRS
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 47
MetricValuePeriodScopeSource row
Revenue¥124.8bn2024-04-01 → 2024-09-30Cons.Revenue IFRS
Revenue¥238.9bn2023-04-01 → 2024-03-31Cons.Revenue IFRS (5-year summary)
Revenue¥115.8bn2023-04-01 → 2023-09-30Cons.Revenue IFRS
Operating income¥29.0bn2024-04-01 → 2024-09-30Cons.Operating profit loss IFRS
Operating income¥34.6bn2023-04-01 → 2023-09-30Cons.Operating profit loss IFRS
Profit before tax¥29.1bn2024-04-01 → 2024-09-30Cons.Profit loss before tax IFRS
Profit before tax¥68.8bn2023-04-01 → 2024-03-31Cons.Profit loss before tax IFRS (5-year summary)
Profit before tax¥37.3bn2023-04-01 → 2023-09-30Cons.Profit loss before tax IFRS
Net income (owners)¥17.3bn2024-04-01 → 2024-09-30Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥45.3bn2023-04-01 → 2024-03-31Cons.Profit loss attributable to owners of parent IFRS (5-year summary)
Net income (owners)¥23.4bn2023-04-01 → 2023-09-30Cons.Profit loss attributable to owners of parent IFRS
Net income¥19.6bn2024-04-01 → 2024-09-30Cons.Profit loss IFRS
Net income¥25.1bn2023-04-01 → 2023-09-30Cons.Profit loss IFRS
Total assets¥491.5bnat 2024-09-30Cons.Assets IFRS
Total assets¥490.8bnat 2024-03-31Cons.Assets IFRS
Total assets¥461.0bnat 2023-09-30Cons.Total assets IFRS (5-year summary)
Total liabilities¥127.0bnat 2024-09-30Cons.Liabilities IFRS
Total liabilities¥124.1bnat 2024-03-31Cons.Liabilities IFRS
Net assets / equity¥364.4bnat 2024-09-30Cons.Equity IFRS
Net assets / equity¥366.7bnat 2024-03-31Cons.Equity IFRS
Net assets / equity¥345.2bnat 2023-09-30Cons.Equity IFRS
Net assets / equity¥309.5bnat 2023-03-31dCons.Equity IFRS
Equity (owners)¥349.5bnat 2024-09-30Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥351.9bnat 2024-03-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥331.6bnat 2023-09-30Cons.Equity attributable to owners of parent IFRS (5-year summary)
Cash & equivalents¥148.1bnat 2024-09-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥149.7bnat 2024-03-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥135.1bnat 2023-09-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥118.3bnat 2023-03-31dCons.Cash and cash equivalents IFRS
Operating cash flow¥23.6bn2024-04-01 → 2024-09-30Cons.Net cash provided by used in operating activities IFRS
Operating cash flow¥58.3bn2023-04-01 → 2024-03-31Cons.Cash flows from used in operating activities IFRS (5-year summary)
Operating cash flow¥26.8bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in operating activities IFRS
Investing cash flow−¥11.3bn2024-04-01 → 2024-09-30Cons.Net cash provided by used in investing activities IFRS
Investing cash flow−¥39.5bn2023-04-01 → 2024-03-31Cons.Cash flows from used in investing activities IFRS (5-year summary)
Investing cash flow−¥28.3bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in investing activities IFRS
Financing cash flow−¥12.6bn2024-04-01 → 2024-09-30Cons.Net cash provided by used in financing activities IFRS
Financing cash flow¥9.4bn2023-04-01 → 2024-03-31Cons.Cash flows from used in financing activities IFRS (5-year summary)
Financing cash flow¥15.3bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in financing activities IFRS
EPS (basic)¥25.472024-04-01 → 2024-09-30Cons.Basic earnings loss per share IFRS
EPS (basic)¥66.682023-04-01 → 2024-03-31Cons.Basic earnings loss per share IFRS (5-year summary)
EPS (basic)¥34.472023-04-01 → 2023-09-30Cons.Basic earnings loss per share IFRS
EPS (diluted)¥25.42024-04-01 → 2024-09-30Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥66.632023-04-01 → 2024-03-31Cons.Diluted earnings loss per share IFRS (5-year summary)
EPS (diluted)¥34.452023-04-01 → 2023-09-30Cons.Diluted earnings loss per share IFRS
Equity ratio71.1%at 2024-09-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio71.7%at 2024-03-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio71.9%at 2023-09-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 54
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2024-04-01 → 2024-09-30−¥1.9bn
Reconciling Itemsreconcilingrevenue intersegment2024-04-01 → 2024-09-30−¥1.9bn
Reconciling Itemsreconcilingsegment profit2024-04-01 → 2024-09-30−¥1.7bn
jpcrp040300-q2r_E05425-000Career Solutionreportable segmentrevenue2024-04-01 → 2024-09-30¥11.6bn
jpcrp040300-q2r_E05425-000Career Solutionreportable segmentrevenue external2024-04-01 → 2024-09-30¥11.6bn
jpcrp040300-q2r_E05425-000Career Solutionreportable segmentrevenue intersegment2024-04-01 → 2024-09-30¥18m
jpcrp040300-q2r_E05425-000Career Solutionreportable segmentsegment profit2024-04-01 → 2024-09-30¥4.1bn
jpcrp040300-q2r_E05425-000Evidence Solutionreportable segmentrevenue2024-04-01 → 2024-09-30¥11.9bn
jpcrp040300-q2r_E05425-000Evidence Solutionreportable segmentrevenue external2024-04-01 → 2024-09-30¥11.8bn
jpcrp040300-q2r_E05425-000Evidence Solutionreportable segmentrevenue intersegment2024-04-01 → 2024-09-30¥100m
jpcrp040300-q2r_E05425-000Evidence Solutionreportable segmentsegment profit2024-04-01 → 2024-09-30¥1.9bn
jpcrp040300-q2r_E05425-000Medical Platformreportable segmentrevenue2024-04-01 → 2024-09-30¥42.5bn
jpcrp040300-q2r_E05425-000Medical Platformreportable segmentrevenue external2024-04-01 → 2024-09-30¥40.7bn
jpcrp040300-q2r_E05425-000Medical Platformreportable segmentrevenue intersegment2024-04-01 → 2024-09-30¥1.7bn
jpcrp040300-q2r_E05425-000Medical Platformreportable segmentsegment profit2024-04-01 → 2024-09-30¥14.6bn
jpcrp040300-q2r_E05425-000Overseasreportable segmentrevenue2024-04-01 → 2024-09-30¥38.0bn
jpcrp040300-q2r_E05425-000Overseasreportable segmentrevenue external2024-04-01 → 2024-09-30¥38.0bn
jpcrp040300-q2r_E05425-000Overseasreportable segmentrevenue intersegment2024-04-01 → 2024-09-30¥28m
jpcrp040300-q2r_E05425-000Overseasreportable segmentsegment profit2024-04-01 → 2024-09-30¥6.6bn
jpcrp040300-q2r_E05425-000Site Solutionreportable segmentrevenue2024-04-01 → 2024-09-30¥21.6bn
jpcrp040300-q2r_E05425-000Site Solutionreportable segmentrevenue external2024-04-01 → 2024-09-30¥21.6bn
jpcrp040300-q2r_E05425-000Site Solutionreportable segmentrevenue intersegment2024-04-01 → 2024-09-30¥6m
jpcrp040300-q2r_E05425-000Site Solutionreportable segmentsegment profit2024-04-01 → 2024-09-30¥3.0bn
—segment totalrevenue2024-04-01 → 2024-09-30¥125.6bn
—segment totalrevenue external2024-04-01 → 2024-09-30¥123.7bn
—segment totalrevenue intersegment2024-04-01 → 2024-09-30¥1.9bn
—segment totalsegment profit2024-04-01 → 2024-09-30¥30.3bn
Reconciling Itemsreconcilingrevenue2023-04-01 → 2023-09-30−¥1.8bn
Reconciling Itemsreconcilingrevenue intersegment2023-04-01 → 2023-09-30−¥1.8bn
Reconciling Itemsreconcilingsegment profit2023-04-01 → 2023-09-30¥125m
jpcrp040300-q2r_E05425-000Career Solutionreportable segmentrevenue2023-04-01 → 2023-09-30¥9.0bn
jpcrp040300-q2r_E05425-000Career Solutionreportable segmentrevenue external2023-04-01 → 2023-09-30¥9.0bn
jpcrp040300-q2r_E05425-000Career Solutionreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥21m
jpcrp040300-q2r_E05425-000Career Solutionreportable segmentsegment profit2023-04-01 → 2023-09-30¥3.3bn
jpcrp040300-q2r_E05425-000Evidence Solutionreportable segmentrevenue2023-04-01 → 2023-09-30¥13.8bn
jpcrp040300-q2r_E05425-000Evidence Solutionreportable segmentrevenue external2023-04-01 → 2023-09-30¥13.6bn
jpcrp040300-q2r_E05425-000Evidence Solutionreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥215m
jpcrp040300-q2r_E05425-000Evidence Solutionreportable segmentsegment profit2023-04-01 → 2023-09-30¥3.6bn
jpcrp040300-q2r_E05425-000Medical Platformreportable segmentrevenue2023-04-01 → 2023-09-30¥45.5bn
jpcrp040300-q2r_E05425-000Medical Platformreportable segmentrevenue external2023-04-01 → 2023-09-30¥44.0bn
jpcrp040300-q2r_E05425-000Medical Platformreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥1.5bn
jpcrp040300-q2r_E05425-000Medical Platformreportable segmentsegment profit2023-04-01 → 2023-09-30¥18.4bn
jpcrp040300-q2r_E05425-000Overseasreportable segmentrevenue2023-04-01 → 2023-09-30¥32.7bn
jpcrp040300-q2r_E05425-000Overseasreportable segmentrevenue external2023-04-01 → 2023-09-30¥32.6bn
jpcrp040300-q2r_E05425-000Overseasreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥11m
jpcrp040300-q2r_E05425-000Overseasreportable segmentsegment profit2023-04-01 → 2023-09-30¥7.3bn
jpcrp040300-q2r_E05425-000Site Solutionreportable segmentrevenue2023-04-01 → 2023-09-30¥15.3bn
jpcrp040300-q2r_E05425-000Site Solutionreportable segmentrevenue external2023-04-01 → 2023-09-30¥15.3bn
jpcrp040300-q2r_E05425-000Site Solutionreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥7m
jpcrp040300-q2r_E05425-000Site Solutionreportable segmentsegment profit2023-04-01 → 2023-09-30¥1.8bn
—segment totalrevenue2023-04-01 → 2023-09-30¥116.4bn
—segment totalrevenue external2023-04-01 → 2023-09-30¥114.6bn
—segment totalrevenue intersegment2023-04-01 → 2023-09-30¥1.7bn
—segment totalsegment profit2023-04-01 → 2023-09-30¥34.4bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 642
ItemContextValueUnit
Remeasurements of defined benefit plans net of tax items that will not be reclassified to profit or loss oci IFRSPrior1YTDDuration-2000000JPY
Remeasurements of defined benefit plans net of tax items that will not be reclassified to profit or loss oci IFRSCurrentYTDDuration－JPY
Net change in fair value of equity instruments designated as measured at fair value through other comprehensive income net of tax items that will not be reclassified to profit or loss oci IFRSPrior1YTDDuration258000000JPY
Net change in fair value of equity instruments designated as measured at fair value through other comprehensive income net of tax items that will not be reclassified to profit or loss oci IFRSCurrentYTDDuration-86000000JPY
Total of items that will not be reclassified to profit or loss oci IFRSPrior1YTDDuration256000000JPY
Total of items that will not be reclassified to profit or loss oci IFRSCurrentYTDDuration-86000000JPY
Exchange differences on translation of foreign operations net of tax items that may be reclassified to profit or loss oci IFRSPrior1YTDDuration9185000000JPY
Exchange differences on translation of foreign operations net of tax items that may be reclassified to profit or loss oci IFRSCurrentYTDDuration-5697000000JPY
Share of other comprehensive income of investments accounted for using equity method net of tax items that may be reclassified to profit or loss oci IFRSPrior1YTDDuration3126000000JPY
Share of other comprehensive income of investments accounted for using equity method net of tax items that may be reclassified to profit or loss oci IFRSCurrentYTDDuration-758000000JPY
Total of items that may be reclassified to profit or loss oci IFRSPrior1YTDDuration12311000000JPY
Total of items that may be reclassified to profit or loss oci IFRSCurrentYTDDuration-6455000000JPY
Other comprehensive income IFRSPrior1YTDDuration12567000000JPY
Other comprehensive income IFRSCurrentYTDDuration-6540000000JPY
Comprehensive income IFRSPrior1YTDDuration37702000000JPY
Comprehensive income IFRSCurrentYTDDuration13049000000JPY
Comprehensive income attributable to owners of parent IFRSPrior1YTDDuration35721000000JPY
Comprehensive income attributable to owners of parent IFRSCurrentYTDDuration11291000000JPY
Comprehensive income attributable to non controlling interests IFRSPrior1YTDDuration1982000000JPY
Comprehensive income attributable to non controlling interests IFRSCurrentYTDDuration1758000000JPY
Comprehensive income IFRSPrior1YTDDuration37702000000JPY
Comprehensive income IFRSCurrentYTDDuration13049000000JPY
Equity IFRSPrior2YearInstant_ShareCapitalIFRSMember29192000000JPY
Equity IFRSPrior2YearInstant_CapitalSurplusIFRSMember25081000000JPY
Equity IFRSPrior2YearInstant_TreasurySharesIFRSMember-37000000JPY
Equity IFRSPrior2YearInstant_OtherComponentsOfEquityIFRSMember17180000000JPY
Equity IFRSPrior2YearInstant_RetainedEarningsIFRSMember231214000000JPY
Equity IFRSPrior2YearInstant_EquityAttributableToOwnersOfParentIFRSMember302630000000JPY
Equity IFRSPrior2YearInstant_NonControllingInterestsIFRSMember6888000000JPY
Equity IFRSPrior2YearInstant309518000000JPY
Profit loss IFRSPrior1YTDDuration_RetainedEarningsIFRSMember23406000000JPY
Profit loss IFRSPrior1YTDDuration_EquityAttributableToOwnersOfParentIFRSMember23406000000JPY
Profit loss IFRSPrior1YTDDuration_NonControllingInterestsIFRSMember1730000000JPY
Profit loss IFRSPrior1YTDDuration25136000000JPY
Other comprehensive income IFRSPrior1YTDDuration_OtherComponentsOfEquityIFRSMember12315000000JPY
Other comprehensive income IFRSPrior1YTDDuration_EquityAttributableToOwnersOfParentIFRSMember12315000000JPY
Other comprehensive income IFRSPrior1YTDDuration_NonControllingInterestsIFRSMember252000000JPY
Other comprehensive income IFRSPrior1YTDDuration12567000000JPY
Comprehensive income IFRSPrior1YTDDuration_ShareCapitalIFRSMember－JPY
Comprehensive income IFRSPrior1YTDDuration_CapitalSurplusIFRSMember－JPY
Comprehensive income IFRSPrior1YTDDuration_TreasurySharesIFRSMember－JPY
Comprehensive income IFRSPrior1YTDDuration_OtherComponentsOfEquityIFRSMember12315000000JPY
Comprehensive income IFRSPrior1YTDDuration_RetainedEarningsIFRSMember23406000000JPY
Comprehensive income IFRSPrior1YTDDuration_EquityAttributableToOwnersOfParentIFRSMember35721000000JPY
Comprehensive income IFRSPrior1YTDDuration_NonControllingInterestsIFRSMember1982000000JPY
Comprehensive income IFRSPrior1YTDDuration37702000000JPY
Dividends ss IFRSPrior1YTDDuration_RetainedEarningsIFRSMember-12899000000JPY
Dividends ss IFRSPrior1YTDDuration_EquityAttributableToOwnersOfParentIFRSMember-12899000000JPY
Dividends ss IFRSPrior1YTDDuration_NonControllingInterestsIFRSMember-2464000000JPY
Dividends ss IFRSPrior1YTDDuration-15364000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identityconsolidated 2024-03-31pass
balance sheet identityconsolidated 2024-09-30pass
dei present pass
period resolution pass
statement vs summary · net income attributable to parentconsolidated 2023-04-01/2023-09-30pass
statement vs summary · net income attributable to parentconsolidated 2024-04-01/2024-09-30pass
statement vs summary · operating cash flowconsolidated 2023-04-01/2023-09-30pass
statement vs summary · operating cash flowconsolidated 2024-04-01/2024-09-30pass
statement vs summary · revenueconsolidated 2023-04-01/2023-09-30pass
statement vs summary · revenueconsolidated 2024-04-01/2024-09-30pass
statement vs summary · total assetsconsolidated 2024-03-31pass
statement vs summary · total assetsconsolidated 2024-09-30pass